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Abstract:  
(E)-1-hydroxy-2-methyl-but-2-enyl 4-diphosphate (HMBPP) is an intermediate in the non-
mevalonate pathway for the biosynthesis of isoprenoids and also serves as a very strong activator 
of human T cells expressing V9/V2 receptors. This paper describes the synthesis of 
analogues of HMBPP, in which the diphosphate group is replaced by potential isosteric moieties, 
i.e. carbamate, N-acyl-N’-oxy sulfamate or aminosulfonyl carbamate functionalities. The 
potential of the synthesized analogues to stimulate V9/V2 T cell response or to inhibit GcpE 
and LytB, the last enzymes in the non-mevalonate pathway was assessed. 
 
1. Introduction 
 
Various disease-causing organisms as Plasmodium falciparum (malaria), Bacillus anthracis 
(anthrax), Clostridium botulinum (botulism) and Mycobacterium tuberculosis (tuberculosis) use 
the non-mevalonate biosynthetic pathway to produce isopentenyl diphosphate (IPP) 1 and 
dimethylallyl diphosphate (DMAPP) 2.1,2 These isoprenoids serve as biosynthetic precursors of a 
wide myriad of terpenes3, some of them being essential components in life cycles of any cell 
type. However, in mammals IPP and DMAPP are formed exclusively via the unrelated 
mevalonate pathway. Selective inhibition of the non-mevalonate pathway would therefore be an 
interesting approach to the development of new treatments for important infectious diseases.4 
The non-mevalonate pathway starts with the formation of 1-deoxy-D-xylulose 5-phosphate 5 by 
condensation of pyruvic acid 3 and D-glyceraldehyde 3-phosphate 4 (Scheme 1). Via 2-C-methyl-
D-erythritol 5-phosphate 6 the pathway leads to (E)-1-hydroxy-2-methyl-but-2-enyl 4-
diphosphate (HMBPP) 7. This intermediate is finally transformed to IPP (1) and DMAPP (2), in a 
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reaction catalyzed by the ispH (or LytB) enzyme.5 This enzyme contains an iron-sulfur cluster 
which suggests a radical mechanism of transformation.6  
Interestingly, HMBPP has also been identified as a very strong activator of the human T cells 
expressing V9/V2 receptors.2,7 The T cells constitute 0.5-5% of the human peripheral blood 
T cells, the vast majority of which express the V9/V2 T cell receptor. Activation and 
proliferation of this subset of T cells is observed in infections with pathogens known to possess 
the MEP pathway, such as tuberculosis or malaria. V9V2 T cell activation appears to be 
important in priming and regulating various reactions of the immune system, but its exact 
function is largely unknown.8,9 Nevertheless, the evaluation of natural and synthetic activators of 
V9V2 T cells has new immunomodulatory drugs been repeatedly suggested.10  
Unlike the activation of  T cells by small antigenic peptides, the V9/V2 T cells are activated 
by low molecular weight phosphorylated compounds collectively called phosphoantigens. 
Specific activation of the T lymphocytes was observed after infection with a broad range of 
pathogenic organisms using the non-mevalonate pathway. While IPP and DMAPP appeared to be 
moderate stimulators,11 HMBPP gave an approximately 10000-fold higher response and probably 
represents the only phosphoantigen of physiological importance. This stimulatory effect, 
however, has a high degree of structure specificity.12 It is thus a challenge to find new 
immunoregulating compounds via the syntheses of HMBPP analogues. 
Various syntheses of HMBPP have been reported,13 but until now only few reports on HMBPP-
analogues have appeared.12,14 These analogues, but also other V9/V2 T cell activators as the 
bisphosphonates,15 all contain a diphoshate or phosphonate function. This has serious drawbacks 
from therapeutic perspective, as the charged phosphate of phosphonate group imparts poor 
cellular permeability characteristics. In addition, phosphatases can rapidly cleave the phosphate 
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groups, resulting in a significant or total loss of activity. This paper describes the synthesis of 
new analogues of HMBPP with alternative functionalities for the diphosphate group. These 
analogues potentially constitute valuable tools to antagonize the HMBPP-mediated V9/V2 T 
cell response or to inhibit LytB activity. By extension, they may be valuable tool compounds to 
further clarify the role of V9/V2 T cells in host-pathogen interactions in important diseases like 
tuberculosis. 
 
Scheme 1.   Biosynthesis of IPP (1) and DMAPP (2) via the non-mevalonate pathway 
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2. Results and discussion 
 
Starting from the previously described TBDPS-protected compound 8,16 several analogues were 
synthesized in which a carbamate functionality replaces the diphosphate moiety of HMBPP 
(Scheme 2). Having one partially positive center, this carbamate serves as an isosteric function 
for a monophosphate. The synthesis was pursued by reaction of 8 in CH2Cl2 with different 
isocyanates in the presence of a catalytic amount of triethylamine to give the corresponding 
carbamates 9-13 in very good yields (84-98%). Typically, the nitrogen was substituted with a 
range of aromatic groups possessing different electronic properties as described in the Topliss 
tree.17 The formation of benzylcarbamate 14 required a longer reaction time and resulted in a 
lower yield of 70%. Since it was observed that removal of the TBDPS group using 
tetrabutylammonium fluoride gave purification problems due to the polarity of the final products, 
ammonium fluoride was selected as the reagent of choice. The reaction in methanol at room 
temperature was slow, but reaction rates could be improved by heating up to 50°C. This process 
yielded the analogues 15-20. 
 
Scheme 2.   Synthesis of carbamate analogues 15-20 
8
TBDPSO
O
9: R = Ph
10: R = pMeO-Ph
11: R = pCl-Ph
12: R = pMe-Ph
13: R = 3,4-Cl2-Ph
14: R = Bn
N
H
O
R HO O N
H
O
R
15: R = Ph
16: R = pMeO-Ph
17: R = pCl-Ph
18: R = pMe-Ph
19: R = 3,4-Cl2-Ph
20: R = Bn
a b
TBDPSO
OH
 
Reagents and conditions: a) RNCO, NEt3, CH2Cl2, RT, 70-98%; b) NH4F, MeOH, 50°C, 88-99% 
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Initially an N-acyl sulfamate group was selected as an alternative isostere of the diphosphate 
group, since it also contains two partially positive charged centers. Introduction of this group can 
be performed with the chlorosulfonyl isocyanate reagent. By primary addition of an appropriate 
alcohol, the reagent is transformed into a carbamate protected chlorosulfonamide. In our case, 
best results were obtained by using tert-butanol,18 thus generating a Boc-protecting group, but 
other alcohols like benzylalcohol have been used by others in the past.19 Next the in situ-prepared 
chlorosulfonamide was reacted with alcohol 8, but unfortunately the formed product 21 appeared 
to be unstable. Therefore, we envisaged the synthesis of a series of N-acyl-N’-oxy sulfamide 
analogues. This class of compounds was anticipated to be more stable then the N-acyl sulfamate 
group and can still serve as an isosteric moiety for the diphosphate.  
Thus, alcohol 8 was transformed into a hydroxylamine via a Mitsunobu reaction using N-hydroxy 
phthalimide as the acid in the presence of diisopropylazodicarboxylate and triphenylphosphine. 
This reaction rendered product 22 in a good yield. Deprotection of the phthaloyl group with 
hydrazine hydrate in ethanol proceeded smoothly to give hydroxylamine 23 with 94% yield. This 
product was treated with in situ-prepared N-Boc-chlorosulfonamide as described above to give 
the N-Boc-N’-oxy product 24. In contrast to compound 21, product 24 is very stable. Removal of 
the Boc group was realized by the careful addition of a solution of trifluoroacetic acid in 
dichloromethane at 0°C and maintaining the resulting solution at 0°C for 24 hours.20  
For the acylation of compound 25, literature precedence supported the use of acid chlorides in the 
presence of triethylamine and 4-dimethylaminopyridine,21 but in our case these conditions did not 
render any product at all. Another literature procedure, the direct coupling of the carboxylic acid 
and the amine with a carbodiimide reagent,22 was also completely ineffective. When using 
carboxylic acids activated as the N-hydroxysuccinimide ester and DBU as the base,23 fairly good 
results could be obtained. The best results, however, were generated by performing a 
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transamidation reaction, using thiazolidinethiones as the activated form of the chosen acids24 in 
the presence of DBU. To our knowledge this reagent has never been used before for the acylation 
of sulfamates. This approach gave compounds 26-30 in fair to good yields. Finally, the products 
31-35 were formed by the removal of the protecting group using ammonium fluoride, giving high 
yields (80-97%), except for the acetyl derivative (43%). The intermediate 24 was deprotected by 
the same method to yield product 36 in moderate yield (63%). 
Scheme 3. Synthesis of N-acyl-N’-oxy sulfamate analogues 30-35 
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Reagents and conditions: a) DIAD, PPh3, N-hydroxyphthalimide, THF, 5°C to RT, 4.5h, 85%; b) 
H2NNH2.H2O, THF, EtOH, RT, 4h, 94%; c) ClSO2NHBoc, CH2Cl2, pyridine, 0°C, 84%; d) TFA, 
CH2Cl2, 0°C, 20h, 81%; e) appropriate N-acylthiazolidinethione, DBU, THF, RT, 40-81%; f) 
NH4F, MeOH, RT, 43-97% 
 
Schema 4. Synthesis of aminosulfonyl carbamate analogues 41-44 
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An unusual reverse approach delivers the possibility of coupling two entities via an 
aminosulfonyl carbamate group which represents an isosteric group of the diphosphate moiety.25 
Chlorosulfonyl isocyanate first reacts with the alcohol 8 in toluene at 0°C to form the carbamate 
function. The resulting chlorosulfonyl carbamate could serve as the electrophile for a substitution 
with any amine, but since this intermediate is very unstable and easily hydrolyses, these amines 
should be very pure. The impractical use of, for example, liquid ammonia could be circumvented 
by the addition of 2.2 equivalents of pyridine. The Burgess type salt that is formed is stable to 
water, so even aqueous solutions of an amine can be used to perform the substitution reaction.26 
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This was exemplified by the use of aqueous ammonia in a one-pot reaction to give compound 37 
in 97% yield. Other amines that were used are methylamine, benzylamine and O-TBDPS-
protected hydroxylamine. Deprotection of the hydroxyl function(s) using ammonium fluoride in 
methanol at room temperature finally yielded the compounds 41-44. The yield for hydroxylamine 
analogue 44 was significantly lower (14%) than for the others (88-92%), a result which may be 
explained by stability issues.  
All final compounds were tested in the V9V2 T cell activation assay in parallel with HMBPP 
as positive control. As expected, significant outgrowth of V9V2 T cells was observed with 
HMBPP at concentrations down to 0.1 nM. However, there was no activity with the test 
compounds up to 100 µM. This result supports previous findings that the diphosphate group of 
HMBPP is essential for potent V9V2 T cell activation. It was demonstrated that only very 
minor modifications of this group such as in (E)-4-hydroxy-3-methyl-but-2-enyl-
methylenediphosphonate (HMB-PCP), which represents the bis-phosphonate analogue of 
HMBPP, results in 10,000-fold reduced activity in the V9V2 T cell activation assay.27 A 
QSAR study by Gossman and Oldfield revealed four essential components arranged in the 
appropriate relative geometry are critical for   T cell activation: an H-bond donor (e.g., the OH 
group of HMBPP (7)), a hydrophobic feature (e.g., the methyl group of HMBPP) and two 
negative ionisable groups (e.g., the two pyrophosphate phosphate groups of HMBPP).28 While all 
analogues investigated contain the former two pharmacophore features, our data suggest that the 
polar diphosphate mimetics investigated are unable to bioisosterically replace the pyrophosphate 
moiety of HMBPP, despite the fact that a NH group flanked by a carbonyl and a sulphonamide as 
in 31-36 and 41-44 will be deprotonated at physiological pH.  
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The potential of compounds 15-20 and 31-36 to inhibit GcpE and LytB was also assessed (Table 
1).  At 1mM concentration, carbamate 18 and analogues 32 and 36, both featuring a N-acyl-N’-
oxy sulfamate moiety, were found to marginally inhibit GcpE or LytB. 
 
Table 1. Inhibition of GcpE and LytB activity by the target compounds at 1 mM.  
 
Compound GcpE LytB 
 % residual activity at 1 mM 
15 98 90 
16 96 85 
17 94 89 
18 90 62 
19 81 95 
20 89 92 
31 94 79 
32 66 87 
33 95 98 
34 95 98 
35 99 102 
36 99 61 
 
 
In conclusion, we have reported the syntheses of three types of HMBPP analogues with some 
structurally diverse diphosphate mimicking groups. Incorporation of a carbamate function mimics 
a phosphate group. Also, two isosteres of the diphosphate group were introduced. The N-acyl-N’-
oxy sulfamate function was formed via coupling of the isoprenoid alcohol and an in situ-
protected chlorosulfamide, followed by deprotection and acylation using thiazolidinethione 
reagents. The aminosulfonyl carbamate moiety was prepared via a three-step one-pot reaction, 
with a Burgess-type salt as an intermediate. The isoprenoid part of HMBPP was left unchanged. 
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All compounds investigated failed to show significant biological activity.  
 
 
4. Experimental section 
 
General procedure for the synthesis of compounds 9-14. To a 0.1M solution of compound 8 in 
dry dichloromethane were added the appropriate isocyanate (1.1 eq) and triethylamine (0.1 eq). 
The reaction mixture was stirred at room temperature until completion was determined via TLC-
analyses. The reaction was quenched by the addition of methanol, and the mixture was 
concentrated under reduced pressure. The resulting residue was purified by column 
chromatography to yield compounds 9-14. 
 
(2E)-4-(tert-butyldiphenylsilyloxy)-3-methylbut-2-en-1-yl phenylcarbamate 9  
Preparation of the title compound according to general procedure described above gave 127 mg 
colourless oil (90%). Rf 0.23 (hexane/ethylacetate 9/1); 1H-NMR (300.01 MHz, aceton-d6)  8.65 
(1H, br s), 7.74-7.69 (4H, m), 7.60-7.57 (2H, m), 7.49-7.39 (6H, m), 7.33-7.26 (2H, m), 7.01 (1H, 
ddt, J = 7.6, 7.0, 1.2 Hz), 5.81 (1H, tqt, app. t sext, J = 7.0, 1.5 Hz), 4.73 (2H, dq, app. br dd, J = 
7.0, 0.6 Hz), 4.15 (2H, q, J = 0.6 Hz), 1.72 (3H, m), 1.06 (9H, s); 13C-NMR (75.00 MHz, aceton-
d6)  153.8 (C), 139.8 (C), 139.7 (C), 135.6 (CH), 133.6 (C), 130.1 (CH), 128.9 (CH), 128.0 
(CH), 122.7 (CH), 118.5 (CH), 67.9 (CH2), 60.8 (CH2), 26.5 (CH3), 19.2 (C), 13.0 (CH3); Exact 
mass (ESI-MS): calculated for C28H33NO3Si [M+Na+] 482.2128; found 482.2121 
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General procedure for the synthesis of compounds 15-20. To a 0.2M solution of the 
carbamates 9-14 in methanol was added ammonium fluoride. The reaction mixture was heated to 
50°C and stirred as such until complete reaction was visible by TLC-analyses. Concentrating 
under reduced pressure gave a residue which was purified by column chromatography, to afford 
the desired unprotected carbamates 15-20.  
 
(2E)-4-hydroxy-3-methylbut-2-en-1-yl phenylcarbamate 15  
Preparation of the title compound according to general procedure described above gave 47 mg 
colourless oil (94%). Rf 0.23 (hexane/ethylacetate 1/1); 1H-NMR (300.01 MHz, aceton-d6)  8.60 
(1H, br s), 7.58-7.54 (2H, m), 7.32-7.25 (2H, m), 7.03-6.98 (1H, m), 5.65 (1H, tqt, app. t sext, J = 
7.0, 1.5 Hz), 4.68 (2H, br dd, J = 7.0, 0.6 Hz), 3.97-3.90 (3H, m); 13C-NMR (75.00 MHz, aceton-
d6)  153.8 (C), 141.5 (C), 139.7 (C), 128.9 (CH), 122.7 (CH), 118.4 (CH), 118.0 (CH), 66.5 
(CH2), 60.9 (CH2), 13.1 (CH3); Exact mass (ESI-MS): calculated for C12H15NO3 [M+Na+] 
244.0950; found 244.0942 
 
 
N-{[(2E)-4-(tert-butyldiphenylsilyloxy)-3-methylbut-2-en-1-yl]oxy} phtalimide 22 
Compound 8 (5.00 g, 14.68 mmol), triphenylphosphine (4.62 g, 17.62 mmol, 1.2 eq) and N-
hydroxyphthalimide (2.87 g, 17.62 mmol, 1.2 eq) were dissolved in dry THF (58.72 mL) and the 
solution was cooled to 5°C. Diisopropyl azodicarboxylate (3.47 mL, 17.62 mmol, 1.2 eq) was 
added dropwise. The reaction was stirred below 10°C for 3 hours, and then allowed to warm up 
to room temperature. After 1.5 hours the reaction mixture was concentrated under reduced 
pressure. The resulting residue was purified via column chromatography (hexane/ethyl acetate 
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8/2) to give pure 22 (6.07 g, 85%) as an oil. 1H-NMR (300.01 MHz, DMSO-d6)  7.87 (4H, m), 
7.61-7.58 (4H, m), 7.47-7.39 (6H, m), 5.87 (1H, tqt, app. t sext, J = 7.5, 1.5 Hz), 4.80 (2H, d, J = 
7.8 Hz), 4.05 (2H, s), 1.60 (3H, s), 0.98 (9H, s); 13C-NMR (75.00 MHz, DMSO-d6)  164.3 (C), 
144.4 (C), 135.9 (CH), 135.8 (CH), 133.7 (C), 130.9 (CH), 129.4 (C), 128.9 (CH), 124.2 (CH), 
116.3 (CH), 73.6 (CH2), 67.9 (CH2), 27.5 (CH3), 19.7 (C), 14.3 (CH3); Exact mass (ESI-MS): 
calculated for C29H31NO4Si [M+K+] 524.1659; found 524.1655 
 
(2E)-4-(aminooxy)-1-(tert-butyldiphenylsilyloxy)-2-methyl-but-2-ene 23 
To a solution of 22 (11.14 g, 22.94 mmol) in THF (57.35 mL) and ethanol (57.35 mL) was added 
hydrazine hydrate (3.345 mL, 68.82 mmol). The reaction mixture was stirred at room temperature 
for 4 hours. It was diluted with ether (500 mL) and washed with water (2 x 200 mL) and brine 
(150 mL). Drying over Na2SO4, filtration and concentration under reduced pressure gave a 
residue that was purified by column chromatography (dichloromethane/methanol 99/1) to yield 
pure 23 (7.64 g, 94%) as an oil. 1H-NMR (300.01 MHz, DMSO-d6)  7.65-7.60 (4H, m), 7.50-
7.40 (6H, m), 5.89 (2H, br s), 5.65 (1H, tqt, app. t sext, J = 6.6, 1.5 Hz), 4.12 (2H, dd, J = 6.6 Hz, 
0.9 Hz), 4.07 (2H, s), 1.58 (3H, m), 1.01 (9H, s); 13C-NMR (75.00 MHz, DMSO-d6)  137.4 (C), 
134.8 (CH), 132.9 (C), 129.8 (CH), 127.8 (CH), 119.4 (CH), 71.0 (CH2), 67.5 (CH2), 26.5 (CH3), 
18.8 (C), 13.4 (CH3); Exact mass (ESI-MS): calculated for C21H29NO2Si [M+H+] 356.2045; 
found 356.2036  
  
tert-butyl [({[(2E)-4-(tert-butyldiphenylsilyloxy)-3-methylbut-2-en-1-yl]oxy}amino)sulfonyl] 
carbamate 24 
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To a solution of chlorosulfonyl isocyanate (1.13 mL, 12.95 mmol, 5 eq) in dry dichloromethane 
(20 mL), cooled to 0°C, was added dropwise a solution of tert-butanol (1.30 mL, 13.73 mmol, 5.3 
eq) in dry dichloromethane (4 mL). The mixture was stirred at 0°C for 1.5 hours and then added 
dropwise to a solution of 23 (920 mg, 2.59 mmol) in dry pyridine (10.36 mL), cooled to 0°C. The 
reaction mixture was allowed to warm up to room temperature slowly, and stirred for 17 hours. 
Reaction work-up was performed by diluting with ethyl acetate (150 mL), washing with 5% citric 
acid solution (2 x 150 mL), water (150 mL) and brine (150 mL). Drying over MgSO4, filtration 
and concentration under reduced pressure gave a residue that was purified by column 
chromatography (dichloromethane/ethanol 99/1) to yield pure 24 (1.16 g, 84%) as an oil. 1H-
NMR (300.01 MHz, aceton-d6)  10.08 (1H, br s), 8.86 (1H, br s), 7.74-7.69 (4H, m), 7.50-7.40 
(6H, m), 5.78 (1H, tqt, app. t sext, J = 6.9, 1.5 Hz), 4.57 (2H, dd, J = 6.9, 0.6 Hz), 4.15 (2H, m), 
1.68 (3H, m), 1.47 (9H, s), 1.07 (9H, s); Exact mass (ESI-MS): calculated for C26H38N2O6SSi 
[M+Na+] 557.2117; found 557.2106 
 
N-{[(2E)-4-(tert-butyldiphenylsilyloxy)-3-methylbut-2-en-1-yl]oxy}sulfamide 25 
To a solution of 24 (2.760 g,  5.16 mmol) in dry dichloromethane (10.3 mL) was added at 0°C a 
50% solution of trifluoroacetic acid in dichloromethane (9 mL) in a dropwise manner over 10 
hours. The reaction was then stirred at 0°C for another 10 hours. The reaction mixture was 
concentrated and the remaining residue was co-evaporated with dichloromethane (20 mL) two 
times. Purification by column chromatography (dichloromethane/ethanol 98/2) gave pure 25 
(1.806 g, 81%) as an oil. Rf 0.24 (dichloromethane/ethanol 98/2); 1H-NMR (300.01 MHz, aceton-
d6)  8.42 (1H, br s), 7.73-7.70 (4H, m), 7.47-7.40 (6H, m), 6.31 (2H, m), 5.79 (1J, br t, J = 6.9 
Hz), 4.55 (2H, d, J = 6.9 Hz), 4.14 (2H, s), 1.67 (3H, s), 1.07 (9H, s); 13C-NMR (75.00 MHz, 
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aceton-d6)  140.9 (C), 136.2 (CH), 134.3 (C), 130.7 (CH), 128.6 (CH), 119.2 (CH), 72.7 (CH2), 
68.8 (CH2), 27.2 (CH3), 19.8 (C), 13.9 (CH3); Exact mass (ESI-MS): calculated for 
C21H30N2O4SSi [M+H+] 435.1773; found 435.1770 
 
General procedure for the synthesis of the compounds 26-29 
To a 0.2 M solution of 25 in dry THF were added the appropriate thiazolidinethione reagent (1 
eq) and DBU (1 eq). The reaction was stirred at room temperature until completion. 
Tetramethylguanidine (0.2 eq) was added and stirring was continued for 1 hour. Next the reaction 
mixture was diluted with dichloromethane and washed with 1N solution of HCl and brine. Drying 
over MgSO4, filtration and concentration under reduced pressure gave a residue that was purified 
by column chromatography to give the respective compounds 26-29. 
 
N-[({[(2E)-4-(tert-butyldiphenylsilyloxy)-3-methylbut-2-en-1-yl]oxy}amino)sulfonyl] 
benzamide 26 
Preparation of the title compound according to general procedure described above gave 100 mg 
as a colourless oil (62%). 1H-NMR (300.01 MHz, aceton-d6) 11.00 (1H, br s), 9.03 (1H, s), 
8.06-8.03 (2H, m), 7.71-7.65 (5H, m), 7.57-7.52 (2H, m), 7.45-7.36 (6H, m), 5.76 (1H, tqt, app. t 
sext, J = 6.9, 1.5 Hz), 4.58 (2H, dd, J = 6.9, 0.6 Hz), 4.13 (2H, m), 1.67 (3H, m), 1.05 (9H, s); 
13C-NMR (75.00 MHz, aceton-d6)  166.7 (C), 142.2 (C), 136.3 (CH), 134.3 (C), 132.5 (C), 
130.7 (CH), 129.7 (CH), 129.2 (CH), 128.7 (CH), 118.2 (CH), 73.4 (CH2), 68.8 (CH2), 27.2 
(CH3), 19.8 (C), 13.9 (CH3); Exact mass (ESI-MS): calculated for C28H34N2O5SSi [M+K+] 
577.1594; found 577.1582 
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N-[({[(2E)-4-(tert-butyldiphenylsilyloxy)-3-methylbut-2-en-1-yl]oxy}amino)sulfonyl] 
cyclohexane-carboxamide 30 
Preparation of the title compound according to general procedure described above gave 186 mg 
white crystals (81%). mp 133-134°C; 1H-NMR (300.01 MHz, aceton-d6)  10.43 (1H, br s), 8.75 
(1H, s), 7.73-7.69 (4H, m), 7.48-7.40 (6H, m), 5.77 (1H, tqt, app. t sext, J = 6.9, 1.5 Hz), 4.56 
(2H, dd, J = 6.9, 0.6 Hz), 4.14 (2H, br d, J = 0.9 Hz), 2.42 (1H, tt, J = 11.2, 3.2 Hz), 1.90-1.85 
(2H, m), 1.78-1.72 (2H, m), 1.67 (3H, m), 1.65-1.60 (1H, m), 1.50-1.19 (5H, m), 1.07 (9H, s); 
13C-NMR (75.00 MHz, aceton-d6)  175.7 (C), 141.9 (C), 136.3 (CH), 134.3 (C), 130.7 (CH), 
128.7 (CH), 118.2 (CH), 73.3 (CH2), 68.7 (CH2), 45.3 (CH), 29.7 (CH2), 27.2 (CH3), 26.3 (CH2), 
26.0 (CH2), 19.9 (C), 13.9 (CH3); Exact mass (ESI-MS): calculated for C28H40N2O5SSi [M+Na+] 
567.2325; found 567.2319 
 
General procedure for the synthesis of compounds 31-36 
To a 0.2M solution of compounds 26-30 in methanol was added ammonium fluoride (2 eq). The 
mixture was stirred at room temperature until the reaction was complete as indicated by TLC-
analysis. Removal of solvent under reduced pressure gave a residue that was purified by column 
chromatography, to yield compounds 31-36. 
N-[({[(2E)-4-hydroxy-3-methylbut-2-en-1-yl]oxy}amino)sulfonyl]benzamide 31 
Preparation of the title compound according to general procedure described above gave 91 mg as 
a gum (91%). 1H-NMR (300.01 MHz, aceton-d6)  8.95 (1H, br s), 8.06-8.02 (2H, m), 7.67-7.61 
(1H, m), 7.55-7.48 (2H, m), 5.59 (1H, tqt, app. t sext, J = 6.9, 1.5 Hz), 4.53 (2H, dd, J = 6.9, 0.6 
Hz), 3.93 (2H, s), 1.65 (3H, m); 13C-NMR (75.00 MHz, aceton-d6)  143.5 (C), 134.0 (CH), 
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133.2 (C), 129.5 (CH), 129.3 (CH), 117.9 (CH), 73.5  (CH2), 67.2 (CH2), 13.9 (CH3); Exact mass 
(ESI-MS): calculated for C12H16N2O5S [M+Na+] 323.0678; found 323.0669 
 
General procedure for the synthesis of compounds 37-40 
To a 0.75M solution of 8 in dry toluene, cooled to 0°C, was added dropwise chlorosulfonyl 
isocyanate (1 eq). After stirring for 30 minutes, the reaction is triturated to a concentration of 0.1 
M by the addition of dry toluene. Pyridine (2.2 eq) was added and stirring was continued for 30 
minutes at 0°C. Subsequently, a solution of the appropriate amine (6 eq) in water or THF was 
added. The reaction was stirred at 0°C for 2 hours and than at room temperature until completion 
was noted. The reaction mixture was poured out into a mixture of water and EtOAc. The pH was 
lowered to 1 by adding concentrated sulfuric acid. The aqueous layer was extracted with EtOAc 
and the combined organic layers were washed with brine. After drying over MgSO4, filtering and 
concentrating of the solution, a residue was obtained that was purified by column 
chromatography to yield compounds 37-40. 
 
(2E)-4-(tert-butyldiphenylsilyloxy)-3-methylbut-2-en-1-yl (aminosulfonyl)carbamate 37 
Preparation of the title compound according to general procedure described above gave 136 mg 
white crystals (97%). Rf 0.22 (hexane/ethylacetate 65/35); mp 78-79°C; 1H-NMR (300.01 MHz, 
aceton-d6)  9.92 (1H, br s), 7.73-7.69 (4H, m), 7.50-7.41 (6H, m), 6.66 (2H, br s), 5.78 (1H, tqt, 
t sext, J = 7.0, 1.5 Hz), 4.75 (2H, dd, J = 7.0, 0.6 Hz), 4.15 (2H, br s), 3.41 (3H, m), 1.06 (9H, s); 
13C-NMR (75.00 MHz, aceton-d6)  152.3 (C), 140.8 (C), 135.6 (CH), 133.5 (C), 130.1 (CH), 
128.1 (CH), 117.6 (CH), 67.9 (CH2), 62.1 (CH2), 26.6 (CH3), 19.2 (C), 13.1 (CH3); Exact mass 
(ESI-MS): calculated for C22H30N2O5SSi [M+Na+] 485.1543; found 485.1537 
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General procedure for the synthesis of compounds 41-44 
To a 0.2M solution of compounds 36-40 in methanol was added ammonium fluoride. The 
reaction was stirred at room temperature until completion was determined by TLC-analysis. 
Removal of the solvent under reduced pressure gave a residue that was purified by column 
chromatography to yield compounds 41-44. 
 
(2E)-4-hydroxy-3-methylbut-2-en-1-yl (aminosulfonyl)carbamate 41 
Preparation of the title compound according to general procedure described above gave 35 mg as 
a sticky oil (92%). Rf 0.15 (dichloromethane/methanol 9/1); 1H-NMR (300.01 MHz, aceton-d6) 
11.08 (1H, br s), 7.39 (2H, br s), 5.53 (1H, tqt, app. t sext, J = 7.3, 1.5 Hz), 4.90 (1H, t, J = 5.6 
Hz), 4.64 (2H, d, J = 7.0 Hz), 3.82 (2H, br d, J = 5.3 Hz), 1.62 (3H, br s); 13C-NMR (75.00 MHz, 
aceton-d6)  152.4 (C), 142.4 (C), 117.0 (CH), 66.3 (CH2), 62.1 (CH2), 13.1 (CH3); Exact mass 
(ESI-MS): calculated for C6H12N2O5S [M+Na+] 247.0365; found 247.0359 
 
GcpE and LytB inhibition assay  
Recombinant GcpE and LytB of Thermus thermophilus and Aquifex aeolicus, respectively, were 
produced as described.29,30 Protein purification and conduct of the enzyme assays was carried out 
under anaerobic conditions in a tent (Coy Laboratory Products, Inc., Grass Lake, USA) floated 
with a gas mixture consisting of 95% N2 and 5% H2. Residual O2 was removed with palladium 
catalysts. Buffers were degassed in an ultrasound bath by bubbling a stream of helium through 
the liquid. Before use, the buffers were equilibrated overnight in the tent under stirring. For the 
enzyme activity assays a spectrophotometer (DU 530 with a Peltier temperature control module, 
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Beckman Coulter) was installed inside the tent. The activity of GcpE and LytB was determined 
by monitoring the oxidation of dithionite-reduced methyl viologen at 732 nm ( = 2200 M-1cm-
1). For the GcpE assay, the reaction mixture consisted of 150 mM NaCl, 30 mM Tris-HCl (pH 
7.5), 0.2% bovine serum albumin (BSA), 2 mM methyl viologen, 1 mM MEcPP and 2.5 µM 
GcpE in a total volume of 0.8 ml. For the LytB assay, the reaction mixture consisted of 150 mM 
NaCl, 30 mM Tris-HCl (pH 7.5), 0.2% BSA, 2 mM methyl viologen, 1 mM HMBPP and 0.1 µM 
LytB in a total volume of 0.8 ml. The methyl viologen was partly reduced by the addition of 
sodium dithionite until an extinction between 1.3 and 1.4 at 732 nm was reached, corresponding 
to 0.59 to 0.64 mM reduced methyl viologen. Typically, 25 µl of a 10 mM sodium dithionite 
stock solution were added to the reaction mixture. The solid sodium dithionite was stored in the 
oxygen-free tent and the stock solution freshly prepared under anaerobic conditions. For the 
inhibition assays, the test compounds were dissolved in DMSO at 100 mM and added to the 
reaction mixture at a final concentration of 1 mM. The activity was recorded in comparison to a 
mock control with DMSO.   
 
V9Vδ2 T cell activation assay  
Flow cytometric analysis of human V9Vδ2 T cells was basically performed as described.31 2 x 
105 peripheral blood mononuclear cells (PBMC) were seeded in 200 ml RPMI 1640 medium 
supplemented with 25 mM HEPES, 2 mM L-glutamine, 25 µg/ml gentamycin, 10 U/ml 
recombinant human interleukin-2 and 10% human AB serum. The test samples were dissolved in 
DMSO at 10 mM and added to the assay in 3-fold serial dilutions ranging from 0.14 µM to 100 
µM. As negative control, DMSO was used at the same dilutions. As positive control, HMBPP in 
a 10-fold serial dilution ranging form 0.01 nM and 10 µM was used. All compounds were tested 
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in duplicates with PBMCs from 3 different donors. After incubation for 6 days at 37°C and 5 % 
CO2, the cells were analysed on an Epics XL flow cytometer supported with Expo32 software 
(Beckman Coulter), using CD3-FITC and TCRVgamma9-PC5 antibodies (Beckman Coulter).  
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